The Effects of β -Glucans on Dendritic Cells and Implications for Cancer Therapy

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

The Effects of β -Glucans on Dendritic Cells and Implications for Cancer Therapy

Anti-Cancer Agents in Medicinal Chemistry, 13(5): 689-698.

Author(s): Sabrin H. Albeituni and Jun Yan.

Affiliation: Tumor Immunobiology Program, James Graham Brown Cancer Center, Clinical & Translational Research Building, Rm 319, University of Louisville, 505 South Hancock Street, Louisville, KY 40202.


β-Glucans are polysaccharides of β-D-glucose extracted from the cell walls of different species of mushrooms, yeast, oat, barley, seaweeds, algae and bacteria. Modern biomedical research has identified β-glucans as biological response modifiers (BRM) with anti-tumor properties that elicit potent immune responses through their recognition by a variety of pattern recognition receptors (PRRs) on dendritic cells (DCs), macrophages and neutrophils. Complement receptor-3 (CR3), lactosylceramides, scavenger receptors and dectin-1 are involved in β-glucan recognition, triggering a series of signaling events that modulate innate and subsequently adaptive immune responses. β-Glucan binding to specific receptors in DCs and macrophages triggers their activation and maturation, increases their antigen-presentation ability and enhances the production of proinflammatory cytokines that stimulate the polarization of TH1 or TH17 responses, and induces the activation of antigen-specific CD8+ cytotoxic T lymphocytes (CTL). Moreover, large β-glucans can be degraded by macrophages into smaller moieties, when released, prime CR3 receptor on neutrophils and natural killer (NK) cells mediating CR3-dependent cellular cytotoxicity (CR3-DCC) of iC3b opsonized tumor cells. Elucidating the molecular mechanisms of β- glucan-induced signaling in immune cells is essential for the design of new therapeutic strategies against cancer. Future studies should be done to translate β-glucan research to the clinic.


Beta glucans, dendritic cells (DC), dectin-1, tumor immunotherapy.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 13
Issue Number: 5
First Page: 689
Last Page: 698
Page Count: 10
DOI: 10.2174/1871520611313050003
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science